Hepatitis C virus (HCV) is a global public health problem, affecting an estimated 180 million people. The high cost of medications is another barrier that prevents wider use of anti-HCV therapy, especially in developing countries. Thus, the treatment of chronic HCV infection represents an unmet medical need. This problem is further aggravated when patients are co-infected with TB and/or HIV. It is agreed that the resurgence in the incidence of global TB is due in part to the AIDS epidemic. There are 9.2 million new cases and 1.7 million deaths from TB annually. According to various sources between one-third and one-half of patients with TB are infected with HIV, which is associated with very poor prognosis and high mortality. Despite the overwhelming burden of disease, no new anti-TB compounds were developed in last 40 years and current strains of TB are becoming increasingly resistant to existing drugs. The occurrence of chronic hepatitis C along with TB and HIV in the same patient presents a challenging task with practically no therapeutic solution. One of promising treatment approaches being pursued by many investigators around the world is so-called therapeutic vaccination, whereby the immune system of a host is modulated to fight off an infectious pathogen.
Phase 2 Trial of V-5 Immunitor (V5) in Patients with Chronic Hepatitis C Co-infected with HIV and Mycobacterium tuberculosis: Olga V. Arjanova, Nathalia D. Prihoda, Larisa V. Yurchenko, Nina I. Sokolenko, Valery M. Frolov, Marina G Tarakanovskaya, Vichai Jirathitikal and Aldar S. Bourinbaiar
Last date updated on November, 2020